SEOUL, Korea, Dec. 6 /PRNewswire/ -- RNL Bio Co., Ltd, (www.rnl.co.kr) a leading biopharmaceutical company specialized in adult stem cell therapeutics announced today that a 46-year-old female, Kang Sook Park's Multiple Sclerosis improved tremendously after receiving stem cell treatment. Park was suffering from MS (Multiple Sclerosis), an autoimmune disease that affects the central nervous system (brain and spinal cord).
Multiple Sclerosis is a disease in which the nerves of the central nervous system degenerate. MS can cause problems with muscle control and strength, vision, balance, feeling, and thinking. MS is caused by damage to the myelin sheath, the protective covering that surrounds nerve cells. When the myelin sheath is damaged, nerve impulses slow down or stop responding. From the many symptoms of MS, numbness or abnormal sensation in any area is predominant.
For the past 20 years, Park suffered from MS. For stem cell injection, she was admitted into Choyang Hospital of Regenerative Medicine in Yanji, China for three weeks. She received stem cells intravenously as well as intrathecally. The injections were given in five intervals -- a total of 1.2 billion cells.
Prior to stem cell treatment, Park suffered from Optic Neuritis -- a common symptom of MS. Some of the symptoms of Optic Neuritis include double vision, vision loss, and uncontrollable rapid eye movements. She was not able to recognize any writing due to her vision loss. After six months of receiving stem cell therapy, Park experienced phenomenal changes. Her vision improved drastically -- she was able to read. Furthermore, it also became possible for her to move her legs using her own muscular strength.
"My legs felt like hollow logs. They were so numb and stiff. However, after receiving stem cell treatment, I can actually feel my legs. I can also tell the difference in cold and warm temperatures. Stem cell therapy brought incredible changes to my physical condition," stated Kang Sook Park.
Park also added, "Receiving stem cell turned my life around. I feel like I am reborn. The fact that I am in this condition brings me new joy. I love the fact that I no longer need anyone's help to get from place to place. I would like to share my experience to others who may have this rare disease. I want to let others know that they can find hope through stem cell treatment, just the way I did."
Dr. Chang Won Kim reported Park's EMG findings before and after the stem cell treatment. "Patients who have an uncommon disease such as MS rarely show improvement or are completely cured. EMG results showed that Park's movement increased both in upper and lower limbs. Reduction in latency suggests that demyelination was also improved. It is extremely difficult for MS patients to use their own strength to even make small movements in the arms or legs. These changes in Park were possible through stem cell therapy."
President and CEO of RNL Bio, Dr. Jeong Chan Ra expressed, "The effective outcomes from stem cell treatment for rare diseases like Multiple Sclerosis can be used in the future. I will do my best to help improve the quality of life for people who are suffering from diseases like MS."
About RNL BIO CO., LTD.
RNL Bio is a premier biotechnology company focused on the research and development of adult derived stem cell therapies. RNL has conducted two Phase II clinical trials for Buerger's Disease as well as Osteoarthritis and one phase I trial for spinal cord injury. RNL is a publically traded company listed in the Korean Stock Exchange (Code 003190) and is expanding its operations throughout the world.
SOURCE RNL Bio Co., Ltd